Drug Profile
Research programme: mTOR inhibitors - Mount Tam Biotechnologies
Alternative Names: TAM-01; TAM-02; TAM-03Latest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator Biotica Technology; University of Cambridge
- Developer Mount Tam Biotechnologies
- Class Antineoplastics; Antiparkinsonians; Macrolides; Polyketides
- Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Multiple sclerosis; Parkinson's disease; Systemic lupus erythematosus
Most Recent Events
- 28 May 2023 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA
- 28 May 2023 No recent reports of development identified for preclinical development in Parkinson's-disease in USA
- 28 Mar 2021 No recent reports of development identified for research development in Cancer in USA